Editorial: Making gene therapy for osteosarcoma a reality

Gene therapy for osteosarcoma is gaining additional momentum with the introduction of delivery vehicles such as hydrogels [52] and modified adenoviral vectors. With safer gene-delivery vehicles being produced, nucleic acid-based therapeutic constructs are becoming more amenable to clinical application. Targets such as ezrin [24], uPAR [28,29] and PEDF [30–32] have been shown to be efficacious for osteosarcoma in animal models. A combination of gene therapy and conventional therapies may yet achieve more complete disease control and warrants further evaluation for osteosarcoma.